ArticleBMC cancer2025
Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.Journal for immunotherapy of cancer · 2026Article
- Clinical, radiological, and histopathological features of checkpoint inhibitor-related pneumonitis: a retrospective cross-sectional analysis of 44 patients who underwent lung biopsy.Translational lung cancer research · 2026Article
- [Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance.Molecular biology reports · 2026Article
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- From inflammatory phenotypes to clinical decisions: a stratified diagnostic and therapeutic framework for CIP.Frontiers in immunology · 2026Review
- Bronchoalveolar lavage fluid in immune checkpoint inhibitor-related pneumonitis: from pathophysiological window to a precision diagnostic tool.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have demonstrated substantial therapeutic efficacy in the treatment of non-small cell lung cancer (NSCLC); however, their clinical application is associated with unique immune-related adverse effects (irAEs). Among these adverse events, immune checkpoint inhibitor-related pneumonitis (CIP) is rare yet serious, which may potentially result in severe respiratory failure, thereby requiring close clinical monitoring. Research specifically focusing on CIP in NSCLC patients treated with PD-1 inhibitors remain limited. This study targets this distinct cohort to comprehensively investigate the clinical and radiological determinants associated with overall survival, applying time-dependent covariate Cox regression to capture the dynamic impact of prognostic factors over time.
methodsA total of 102 NSCLC participants who received immunotherapy with programmed cell death protein-1 (PD-1) inhibitors and then developed CIP were retrospectively enrolled in this study. Univariate and multivariate time-dependent covariate Cox regression models were constructed to determine associations between CIP features and survival benefits of CIP patients.
resultsThe incidence of CIP was 15% (102/680) with a median onset time of 4.6 months. Fifty-one patients (50.0%) were identified as having organizing pneumonia (OP) pattern, followed by nonspecific interstitial pneumonia (NSIP) pattern in 28 patients (27.4%), hypersensitivity pneumonitis (HP) pattern in 6 patients (5.9%), and diffuse alveolar damage (DAD) pattern in 2 patients (2.0%). Additionally, 15 patients (14.7%) were classified as unclassifiable pattern. Kaplan-Meier analysis and Log-rank test indicated that CIP located around the tumor and with reticular opacity were associated with poorer prognosis (P = 0.023, P = 0.013). Compared to those with CIP grades 2-4, patients with CIP grade 1 demonstrated survival benefit with border-line significance (P = 0.049). Multivariate time-dependent covariate Cox regression analysis showed that CIP improvement or not (χ
conclusionsCIP without improvement or resolution, a high percentage of neutrophils and elevated albumin level of peripheral blood examination were independent predictors for the prognosis of NSCLC patients, which may have an implication for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.